OA02.03 Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study
Work
Year: 2024
Type: article
Source: Journal of Thoracic Oncology
Cites:
Cited by: 2
Related to: 10
FWCI: 2.646
Citation percentile (by year/subfield): 79.53
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Zero hunger
Open Access status: closed